These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 30464803)

  • 1. The genomic features associated with high-risk multiple myeloma.
    Walker BA; Morgan GJ
    Oncotarget; 2018 Oct; 9(84):35478-35479. PubMed ID: 30464803
    [No Abstract]   [Full Text] [Related]  

  • 2. [Analysis of the clinical effects and outcome of patients with double-hit high-risk multiple myeloma].
    Liu S; Shang J; Lin Y; Wang ZH; Wei TN; Lin L; Yang T; Chen WM
    Zhonghua Zhong Liu Za Zhi; 2021 Nov; 43(11):1209-1214. PubMed ID: 34794226
    [No Abstract]   [Full Text] [Related]  

  • 3. Concepts of Double Hit and Triple Hit Disease in Multiple Myeloma, Entity and Prognostic Significance.
    Baysal M; Demirci U; Umit E; Kirkizlar HO; Atli EI; Gurkan H; Gulsaran SK; Bas V; Mail C; Demir AM
    Sci Rep; 2020 Apr; 10(1):5991. PubMed ID: 32249811
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical Features and Outcomes of Patients with Double-Hit/Triple-Hit Multiple Myeloma Detected at Relapse.
    Singh C; Panakkal V; Sreedharanunni S; Jandial A; Jain A; Lad D; Prakash G; Khadwal A; Malhotra P
    Indian J Hematol Blood Transfus; 2023 Jan; 39(1):151-153. PubMed ID: 36699422
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Adverse effects of double-hit combining ISS-Ⅲ stage and 1q gain or del (17p) on prognosis of patients with newly diagnosed multiple myeloma].
    Liu XL; Yang YP; Bai J; Yue TT; Yang PY; Zhang Y; Fan HQ; Li W; Jin FY
    Zhonghua Xue Ye Xue Za Zhi; 2019 Nov; 40(11):912-917. PubMed ID: 31856439
    [No Abstract]   [Full Text] [Related]  

  • 6. [Clinical prognosis analysis of patients with "double hit" multiple myeloma].
    Luo TC; Wu LL; Wu H; Lu M; Fu WJ; Du J
    Zhonghua Xue Ye Xue Za Zhi; 2019 Nov; 40(11):918-923. PubMed ID: 31856440
    [No Abstract]   [Full Text] [Related]  

  • 7. A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis.
    Walker BA; Mavrommatis K; Wardell CP; Ashby TC; Bauer M; Davies F; Rosenthal A; Wang H; Qu P; Hoering A; Samur M; Towfic F; Ortiz M; Flynt E; Yu Z; Yang Z; Rozelle D; Obenauer J; Trotter M; Auclair D; Keats J; Bolli N; Fulciniti M; Szalat R; Moreau P; Durie B; Stewart AK; Goldschmidt H; Raab MS; Einsele H; Sonneveld P; San Miguel J; Lonial S; Jackson GH; Anderson KC; Avet-Loiseau H; Munshi N; Thakurta A; Morgan G
    Leukemia; 2019 Jan; 33(1):159-170. PubMed ID: 29967379
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multiple myeloma: 2020 update on diagnosis, risk-stratification and management.
    Rajkumar SV
    Am J Hematol; 2020 May; 95(5):548-567. PubMed ID: 32212178
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Malignant plasmacytes in bone marrow detected by flow cytometry as a predictor for the risk stratification system of multiple myeloma.
    Tian M; Liu Z; Han M; Liu H; Xiang C; Mi F; Deng L; Meng N; Fu R
    Cytometry B Clin Cytom; 2022 Jan; 102(1):44-49. PubMed ID: 34057806
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multiple myeloma: 2022 update on diagnosis, risk stratification, and management.
    Rajkumar SV
    Am J Hematol; 2022 Aug; 97(8):1086-1107. PubMed ID: 35560063
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recent Advances in the Management of Smoldering Multiple Myeloma.
    Madhira BR; Konala VM; Adapa S; Naramala S; Ravella PM; Parikh K; Gentile TC
    World J Oncol; 2020 Apr; 11(2):45-54. PubMed ID: 32284772
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Poor overall survival in hyperhaploid multiple myeloma is defined by double-hit bi-allelic inactivation of
    Ashby C; Tytarenko RG; Wang Y; Weinhold N; Johnson SK; Bauer M; Wardell CP; Schinke C; Thanendrarajan S; Zangari M; van Rhee F; Davies FE; Sawyer JR; Morgan GJ; Walker BA
    Oncotarget; 2019 Jan; 10(7):732-737. PubMed ID: 30774775
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The RAG Model: A New Paradigm for Genetic Risk Stratification in Multiple Myeloma.
    Prideaux SM; Conway O'Brien E; Chevassut TJ
    Bone Marrow Res; 2014; 2014():526568. PubMed ID: 25295194
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The survival impact of CKS1B gains or amplification is dependent on the background karyotype and TP53 deletion status in patients with myeloma.
    Hao S; Lu X; Gong Z; Bassett RL; Hu S; Konoplev SN; Tang G; Li S; Xu J; Khanlari M; Lee HC; Manasanch EE; Weber DM; Orlowski RZ; Medeiros LJ; Lin P
    Mod Pathol; 2021 Feb; 34(2):327-335. PubMed ID: 32908255
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advances in MGUS diagnosis, risk stratification, and management: introducing myeloma-defining genomic events.
    Landgren O
    Hematology Am Soc Hematol Educ Program; 2021 Dec; 2021(1):662-672. PubMed ID: 34889381
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Experts' consensus on the definition and management of high risk multiple myeloma.
    Marcon C; Simeon V; Deias P; Facchin G; Corso A; Derudas D; Montefusco V; Offidani M; Petrucci MT; Zambello R; Stocchi R; Fanin R; Patriarca F
    Front Oncol; 2022; 12():1096852. PubMed ID: 36755858
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Personalised progression prediction in patients with monoclonal gammopathy of undetermined significance or smouldering multiple myeloma (PANGEA): a retrospective, multicohort study.
    Cowan A; Ferrari F; Freeman SS; Redd R; El-Khoury H; Perry J; Patel V; Kaur P; Barr H; Lee DJ; Lightbody E; Downey K; Argyelan D; Theodorakakou F; Fotiou D; Liacos CI; Kanellias N; Chavda SJ; Ainley L; Sandecká V; Pospíšilová L; Minarik J; Jungova A; Radocha J; Spicka I; Nadeem O; Yong K; Hájek R; Kastritis E; Marinac CR; Dimopoulos MA; Get G; Trippa L; Ghobrial IM
    Lancet Haematol; 2023 Mar; 10(3):e203-e212. PubMed ID: 36858677
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gene Expression Profiling in Multiple Myeloma: Redefining the Paradigm of Risk-Adapted Treatment.
    Cerchione C; Usmani SZ; Stewart AK; Kaiser M; Rasche L; Kortüm M; Mateos MV; Spencer A; Sonneveld P; Anderson KC
    Front Oncol; 2022; 12():820768. PubMed ID: 35211412
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transcriptional signature of TP53 biallelic inactivation identifies a group of multiple myeloma patients without this genetic condition but with dismal outcome.
    De Ramón C; Rojas EA; Cardona-Benavides IJ; Mateos MV; Corchete LA; Gutiérrez NC
    Br J Haematol; 2022 Nov; 199(3):344-354. PubMed ID: 35983648
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Centrosome associated genes pattern for risk sub-stratification in multiple myeloma.
    Kryukov F; Nemec P; Radova L; Kryukova E; Okubote S; Minarik J; Stefanikova Z; Pour L; Hajek R
    J Transl Med; 2016 May; 14(1):150. PubMed ID: 27234807
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.